JP2022527108A5 - - Google Patents

Info

Publication number
JP2022527108A5
JP2022527108A5 JP2021558626A JP2021558626A JP2022527108A5 JP 2022527108 A5 JP2022527108 A5 JP 2022527108A5 JP 2021558626 A JP2021558626 A JP 2021558626A JP 2021558626 A JP2021558626 A JP 2021558626A JP 2022527108 A5 JP2022527108 A5 JP 2022527108A5
Authority
JP
Japan
Prior art keywords
sequence
pharmaceutical composition
sequence number
sense strand
antisense strand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021558626A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527108A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/025125 external-priority patent/WO2020205473A1/en
Publication of JP2022527108A publication Critical patent/JP2022527108A/ja
Publication of JP2022527108A5 publication Critical patent/JP2022527108A5/ja
Pending legal-status Critical Current

Links

JP2021558626A 2019-03-29 2020-03-27 Kras関連疾患または障害の治療のための組成物及び方法 Pending JP2022527108A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962826121P 2019-03-29 2019-03-29
US62/826,121 2019-03-29
PCT/US2020/025125 WO2020205473A1 (en) 2019-03-29 2020-03-27 Compositions and methods for the treatment of kras associated diseases or disorders

Publications (2)

Publication Number Publication Date
JP2022527108A JP2022527108A (ja) 2022-05-30
JP2022527108A5 true JP2022527108A5 (https=) 2023-04-04

Family

ID=70471081

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021558626A Pending JP2022527108A (ja) 2019-03-29 2020-03-27 Kras関連疾患または障害の治療のための組成物及び方法

Country Status (13)

Country Link
US (1) US20220154189A1 (https=)
EP (1) EP3947681A1 (https=)
JP (1) JP2022527108A (https=)
KR (1) KR20210145213A (https=)
CN (1) CN113924365A (https=)
AU (1) AU2020253823A1 (https=)
BR (1) BR112021018739A2 (https=)
CA (1) CA3134486A1 (https=)
CL (1) CL2021002533A1 (https=)
IL (1) IL286636A (https=)
MX (1) MX2021011928A (https=)
SG (1) SG11202110174PA (https=)
WO (1) WO2020205473A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
EA202190749A1 (ru) 2018-09-10 2021-07-09 Мирати Терапьютикс, Инк. Способы комбинированной терапии
JP2022500385A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス, インコーポレイテッド 組み合わせ療法
EP3849535A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
EP3849537B1 (en) 2018-09-10 2024-10-23 Mirati Therapeutics, Inc. Combination therapies
MX2021002804A (es) 2018-12-05 2021-07-15 Mirati Therapeutics Inc Terapias de combinacion.
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
MX2022002465A (es) 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
WO2021061749A1 (en) 2019-09-24 2021-04-01 Mirati Therapeutics, Inc. Combination therapies
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
EP4225383A4 (en) * 2020-10-08 2024-12-11 Kumquat Biosciences Inc. MODULATORS OF CELLULAR PROLIFERATION AND THEIR USES
JP2023553492A (ja) 2020-12-15 2023-12-21 ミラティ セラピューティクス, インコーポレイテッド アザキナゾリン汎KRas阻害剤
EP4262803A4 (en) 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
JP2024516168A (ja) * 2021-04-22 2024-04-12 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド がんを治療するための組成物および方法
TW202339786A (zh) * 2022-01-21 2023-10-16 日商中外製藥股份有限公司 癌症之治療或預防用醫藥
CN121015887A (zh) * 2025-10-22 2025-11-28 天津市肿瘤医院(天津医科大学肿瘤医院) 预测胰腺癌对kras抑制剂耐药性的生物标志物及其应用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
JPH03503894A (ja) 1988-03-25 1991-08-29 ユニバーシィティ オブ バージニア アランミ パテンツ ファウンデイション オリゴヌクレオチド n‐アルキルホスホラミデート
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5194599A (en) 1988-09-23 1993-03-16 Gilead Sciences, Inc. Hydrogen phosphonodithioate compositions
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5721218A (en) 1989-10-23 1998-02-24 Gilead Sciences, Inc. Oligonucleotides with inverted polarity
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
MY107332A (en) 1990-08-03 1995-11-30 Sterling Drug Inc Compounds and methods for inhibiting gene expression.
US5177196A (en) 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
JPH06505704A (ja) 1990-09-20 1994-06-30 ギリアド サイエンシズ,インコーポレイテッド 改変ヌクレオシド間結合
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
HU9501974D0 (en) 1993-03-31 1995-09-28 Sterling Winthrop Inc Oligonucleotides with amide linkages replacing phosphodiester linkages
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5646269A (en) 1994-04-28 1997-07-08 Gilead Sciences, Inc. Method for oligonucleotide analog synthesis
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
CN1120707C (zh) 1995-11-22 2003-09-10 约翰斯·霍普金斯大学 增强生物分子的细胞摄取的配体
AU733310C (en) 1997-05-14 2001-11-29 University Of British Columbia, The High efficiency encapsulation of charged therapeutic agents in lipid vesicles
DE69941447D1 (de) 1998-01-05 2009-11-05 Univ Washington Erhöhter transport unter benutzung membranzerstörender stoffe
US7737108B1 (en) 2000-01-07 2010-06-15 University Of Washington Enhanced transport using membrane disruptive agents
JP2004501955A (ja) 2000-06-30 2004-01-22 アイネックス ファーマシューティカルズ コーポレイション リポソーム抗新生物薬剤およびその使用
CA2429814C (en) 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
WO2003040395A2 (en) 2001-11-07 2003-05-15 Applera Corporation Universal nucleotides for nucleic acid analysis
EP1661905B9 (en) 2003-08-28 2012-12-19 IMANISHI, Takeshi Novel artificial nucleic acids of n-o bond crosslinkage type
CA2559955C (en) 2004-03-15 2016-02-16 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
EP1750673B1 (en) 2004-05-17 2009-12-02 Tekmira Pharmaceuticals Corporation Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
US7718193B2 (en) 2006-03-16 2010-05-18 University Of Washington Temperature- and pH-responsive polymer compositions
CN101500548A (zh) 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
KR20110020804A (ko) 2008-05-13 2011-03-03 유니버시티 오브 워싱톤 치료제의 세포내 전달을 위한 미셀
CA2972694C (en) 2008-05-13 2020-02-11 University Of Washington Diblock copolymers and polynucleotide complexes thereof for delivery into cells
AU2009246321A1 (en) 2008-05-13 2009-11-19 Phaserx, Inc. Polymeric carrier
WO2009140423A2 (en) 2008-05-13 2009-11-19 University Of Washington Targeted polymer bioconjugates
EP2285853B1 (en) 2008-05-13 2013-02-27 University of Washington Micellic assemblies
JP2012500793A (ja) 2008-08-22 2012-01-12 ユニヴァーシティ オブ ワシントン 細胞内デリバリーのための異種性ポリマーミセル
DK2341943T3 (en) 2008-09-22 2019-02-25 Dicerna Pharmaceuticals Inc COMPOSITIONS AND METHODS OF SPECIFIC INHIBITION OF DSRNA REPRINT WITH MODIFICATIONS
US20110281934A1 (en) 2008-11-06 2011-11-17 Phaserx, Inc. Micelles of hydrophilically shielded membrane-destabilizing copolymers
MX2011004242A (es) 2008-11-06 2011-07-20 Univ Washington Copolimeros multibloque.
KR101728655B1 (ko) 2008-12-18 2017-04-19 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
CN103555722B (zh) 2009-04-03 2016-08-31 戴瑟纳制药公司 利用不对称双链rna特异性抑制kras的方法和组合物
WO2010115202A2 (en) * 2009-04-03 2010-10-07 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna
KR101766408B1 (ko) 2009-06-10 2017-08-10 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
CA3131967A1 (en) 2010-12-29 2012-07-05 F. Hoffman-La Roche Ag Small molecule conjugates for intracellular delivery of nucleic acids
AU2013315543A1 (en) 2012-09-14 2015-04-09 Dicerna Pharmaceuticals, Inc. Methods and compostions for the specific inhibition of MYC by double-stranded RNA
CA2900238A1 (en) 2013-02-22 2014-08-28 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) molecules containing a 2' internucleoside linkage
CN105142614A (zh) 2013-03-14 2015-12-09 迪克纳制药公司 用于配制阴离子试剂的方法
DK3569711T3 (da) 2014-12-15 2021-02-22 Dicerna Pharmaceuticals Inc Ligandmodificerede dobbeltstrengede nukleinsyrer
EP3436585B1 (en) * 2016-04-01 2022-07-20 Avidity Biosciences, Inc. Kras nucleic acids and uses thereof
HUE059718T2 (hu) 2016-09-02 2022-12-28 Dicerna Pharmaceuticals Inc 4'-foszfát analógok és azokat tartalmazó oligonukleotidok
WO2018098352A2 (en) * 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression

Similar Documents

Publication Publication Date Title
JP2022527108A5 (https=)
JP2025000818A (ja) 筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法
JP7007304B2 (ja) B型肝炎感染症治療用のPAPD5又はPAPD7のmRNA減少用核酸分子
KR102728481B1 (ko) Lpa의 유전자 발현을 저해하기 위한 조성물 및 방법
CN114144423B (zh) 使用与免疫检查点抑制剂组合递送的siRNA沉默TGF-BETA 1和COX2以治疗癌症
TW201922264A (zh) 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法
JP2024535888A5 (https=)
JP2005521393A5 (https=)
JP2023539341A5 (https=)
JP2013504603A5 (https=)
CN107532169B (zh) 用于治疗杜兴氏肌肉营养不良症的发动蛋白2抑制剂
JP2022031642A (ja) アンチセンスオリゴヌクレオチド
JP2024514880A5 (https=)
RU2535993C2 (ru) Молекула rnai, нацеливающая тимидилатсинтазу и ее применение
JP2023516392A (ja) アプタマーおよびその使用
JP2009540857A (ja) Bcl−XL特異的siNAを用いる癌治療法
JP7493460B2 (ja) 有機化合物
TWI670064B (zh) 抗病毒劑及治療病毒感染之方法
JP5578498B2 (ja) 抗癌剤キット及び抗癌剤効果増強剤
KR101783444B1 (ko) miR-33-5p 를 이용한 뇌신경세포 보호 물질 스크리닝 방법
US20100310579A1 (en) Method for inhibiting angiogenesis or for treatment of cancer
US20090087434A1 (en) Nfia in glial fate determination, glioma therapy and astrocytoma treatment
WO2022056117A1 (en) Nucleic acid-polypeptide compositions and uses thereof
KR101855900B1 (ko) Setd1a의 발현 또는 활성 억제제를 유효성분으로 함유하는 항암제 내성 유방암의 예방 또는 치료용 약학적 조성물
WO2023040828A1 (zh) 靶向FAP阳性细胞的siRNA缀合物及其药物组合物和应用